• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

DDL 2024 in review

Bell noted that “All propellants, current and future, face threats from environmental legislation.” One of the most discussed issues during the panel was the proposal by the European Chemical Agency (ECHA) to restrict PFAS chemicals over concerns about persistence in the environment. He pointed out that the US Environmental Protection Agency (EPA) does not define HFO 1234ze as a PFAS; however, the ECHA proposal would include restrictions on HFO 1234ze based on characteristics of what Bell called “a negligible breakdown product” of the propellant.

Posters at DDL
Posters at DDL 2024

Bell referred the audience to Honeywell’s poster titled, “HFO-1234ze(E): a safe and green propellant supporting sustainability transition in metered dose inhalers” for documentation of the molecule’s properties, noting especially that the atmospheric lifetime of HFO-1234ze is 12 days versus 12 years for HFA 134a and 36 years for HFA 227ea.

Hardwick described IPAC’s efforts to educate policy makers, including a joint submission from IPAC and IPAC-RS to ECHA which states that “the proposed near-term bans of three medical propellants (HFC-134a, HFC-227ea, and HFO-1234ze(E)) are unsupported by the REACH proposal, inconsistent with conclusions of the European Medicines Agency (EMA) and other regulatory agencies and could represent serious risks for patient care” and requests that all of those propellants be excluded from the restrictions.

The speakers all emphasized the need to retain MDIs as an option for patients and to provide education for regulators, citing misconceptions on the parts of both clinicians and regulators as a cause for concern. Hardwick reported that she has shared papers from RDD and DDL with policy makers as part of the education effort.

During the Q&A session, John Pritchard, the Chairman of Nebuflow and Cardiff Scintigraphics, reiterated the argument he put forth in a presentation at DDL 2022 that the industry is moving too slowly to transition and may run out of time and asked the panel what can be done to convince companies not already reformulating with LGWP propellants to make that move. Hardwick responded that she thinks that the transition is gaining momentum in the industry, citing significant attendance at the CRCG workshop.

Share
« Previous Page 1 2 3 4 5 6Next page »

published on December 23, 2024

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews